June 14, 2017 07:00 PM EDT

With Novartis and Google jumping in, Medicxi unveils a $300M late-stage biotech fund with a transatlantic scope

John Carroll

Editor & Founder

The European venture group Medicxi is staking out some new terrain in biotech investing. And they’re bringing in two big players — Novartis and Google’s Verily …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With Novartis and Google jumping in, Medicxi unveils a $300M late-stage biotech fund with a transatlantic scope

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

With No­var­tis and Google jump­ing in, Medicxi un­veils a $300M late-stage biotech fund with a transat­lantic scope

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

With Novartis and Google jumping in, Medicxi unveils a $300M late-stage biotech fund with a transatlantic scope